NATIONAL INSTITUTES OF HEALTH
- Country
- 🇺🇸United States
- Ownership
- Subsidiary, Private
- Established
- 1948-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.nidcr.nih.gov
Immune Response to Hepatitis C Virus
- Conditions
- Hepatitis C
- First Posted Date
- 2000-09-28
- Last Posted Date
- 2019-12-03
- Target Recruit Count
- 89
- Registration Number
- NCT00006301
- Locations
- 🇺🇸
Occupational Medicine Services, Annandale, Virginia, United States
🇺🇸INOVA Fairfax Hospital, Falls Church, Virginia, United States
🇺🇸Holy Cross Hospital, Silver Spring, Silver Spring, Maryland, United States
Micellar Paclitaxel to Treat Severe Psoriasis
- Conditions
- Psoriasis
- First Posted Date
- 2000-09-15
- Last Posted Date
- 2008-03-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 25
- Registration Number
- NCT00006276
- Locations
- 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States
A Study of the Safety and Efficacy of Tobramycin for Inhalation in Young Children With Cystic Fibrosis
- Conditions
- Cystic Fibrosis
- First Posted Date
- 2000-09-12
- Last Posted Date
- 2010-03-02
- Target Recruit Count
- 98
- Registration Number
- NCT00006280
- Locations
- 🇺🇸
Children's Hospital, Boston, Massachusetts, United States
🇺🇸University of North Carolina - Chapel Hill, Chapel Hill, North Carolina, United States
🇺🇸Stanford University/Lucille Packard Children's Health Services at Stanford, Palo Alto, California, United States
A Study to Determine How and Why HIV-Infected Subjects on Anti-viral Treatment Develop Lipodystrophy
- Conditions
- HIV InfectionsLipodystrophy
- Locations
- 🇺🇸
UT Southwestern Medical Center, Dallas, Texas, United States
Chemotherapy, Stem Cell Transplantation and Donor and Patient Vaccination for Treatment of Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- Drug: Myeloma Immunoglobulin Idiotype VaccineBiological: GMCSF (granulocyte macrophage colony stimulating factor)Biological: GCSF (granulocyte colony stimulating factor)
- First Posted Date
- 2000-08-24
- Last Posted Date
- 2017-10-20
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 20
- Registration Number
- NCT00006184
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Underlying Abnormalities in Fat and Muscle Leading to Lipodystrophy Syndrome
- Conditions
- HIV InfectionsLipodystrophyInsulin Resistance
- Locations
- 🇺🇸
University Hospital at Stony Brook New York, Stony Brook, New York, United States
Sirolimus and Thymoglobulin to Prevent Kidney Transplant Rejection
- First Posted Date
- 2000-08-16
- Last Posted Date
- 2019-09-17
- Target Recruit Count
- 12
- Registration Number
- NCT00006178
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Effects of Potent Antiretroviral Therapy on Kaposi s Sarcoma
- Conditions
- HIV SeropositivityKaposi's SarcomaHIV Infections
- First Posted Date
- 2000-08-11
- Last Posted Date
- 2019-12-12
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 24
- Registration Number
- NCT00006171
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Long Term Interferon for Patients Who Did Not Clear Hepatitis C Virus With Standard Treatment
- Conditions
- Chronic Hepatitis cHepatic CirrhosisCirrhosis, LiverFibrosis, Liver
- Interventions
- Drug: Peginterferon alfa-2a + Ribavirin
- First Posted Date
- 2000-08-09
- Last Posted Date
- 2020-05-12
- Target Recruit Count
- 1050
- Registration Number
- NCT00006164
- Locations
- 🇺🇸
USC School of Medicine, Los Angeles, California, United States
🇺🇸University of Connecticut Health Center, Farmington, Connecticut, United States
🇺🇸University of Texas Southwestern - Dallas, Dallas, Texas, United States
Computer-assisted Diabetes Self-management Interventions
- Conditions
- Diabetes Mellitus, Type 2
- Locations
- 🇺🇸
AMC Cancer Research center, Denver, Colorado, United States